Immunicum AB reveals positive Phase II MERECA clinical trial data
Category: #health  By Paroma Bhattacharya  Date: 2019-08-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Immunicum AB reveals positive Phase II MERECA clinical trial data

Satisfactory safety profile and the positive number of complete responses by the trials firmly justify the prolonged clinical advancement of ilixadencel as an immune primer in solid tumors.

Immunicum AB (publ), a Swedish biopharmaceutical company, has recently announced positive results from the Phase II MERECA (Metastatic Renal Cell Carcinoma) clinical trials which was focused on evaluating the therapeutic impact of merging Sutent® (sunitinib) with ilixadencel.

As per reports, the most significant outcome of this trial was getting 5 complete responses, defined as no further evidence of disease and eradication of the cancerous tumor, without the additional toxicity created by ilixadencel.

However, the median overall survival has not been achieved yet due to a high rate of overall survival in both study arms. The result also validates the continued clinical development of ilixadencel in other solid tumor indications as well as in kidney cancer.

Speaking on the announcement, Dr. Magnus Lindskog, MERECA investigator and Associate Professor at Uppsala University Hospital, said that being a clinical oncologist who specializes in treating kidney cancer patients, the potential of an immune primer that can uphold the advancement of complete responses in advanced-stage patients with a progressive safety profile and tolerability is very exciting, particularly in an indication where a complete response is rare.

He said that it would be a major step forward for the treatment of kidney cancer if this response rate can be replicated on a bigger pivotal trial.

As for Carlos de Sousa, CEO, Immunicum AB (publ), the company’s main aim from MERECA trials was to study the therapeutic benefit of ilixadencel when merged with a standard treatment regimen. Moreover, the astounding number of complete responses in advanced-stage cancer patients is reassuring and highly supportive of their idea for ilixadencel as primary therapy in modern cancer treatment options.

He further added that the company is eager to conduct the complete investigation of the data and use it to accelerate and refine ilixadencel’s clinical advancements.

Source Credit: https://immunicum.se/investors/press-releases/press/?xml_id=1908171

 



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...